Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, today announces that it has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise Eroxon®, the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment, throughout the European […]